Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relief Therapeutics Hldg Ag (OP: RLFTF )

7.280 +0.330 (+4.75%)
Streaming Delayed Price Updated: 10:01 AM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relief Therapeutics Hldg Ag

< Previous 1 2 3 4 5 6 7 Next >
Relief's Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating Nexodyn(R) AOS Highly Effective Treatment to Support Healing of Hard-to-Heal Leg Ulcers
As an Active Cleanser, Nexodyn(R) AOS Shows Superior Wound Healing Performance Compared to Standard of Care GENEVA, SWITZERLAND / ACCESSWIRE / September 30, 2021 / RELIEF THERAPEUTICS Holding SA... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil)
GENEVA, SWITZERLAND / ACCESSWIRE / September 28, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports Half-Year 2021 Results and Provides Corporate Update
GENEVA, SWITZERLAND / ACCESSWIRE / September 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Relief's Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in Peer Reviewed Journal, Nutrients, Indicating Additional Potential Benefits of Its Physiomimic(TM) Technology
- Data In Healthy Volunteers Suggests That APR's Controlled Release Amino Acid Mix, PKU GOLIKE(R) , May Be Key To Reducing Catabolic Events In Patients With Phenylketonuria ("PKU"), Improving... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics Provides Update on Regulatory Interactions in the United Kingdom and European Union Relating to Lead Drug Candidate, RLF-100 (Aviptadil)
GENEVA, SWITZERLAND / ACCESSWIRE / September 13, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE(R) KRUNCH in Germany and Italy
APR Expands PKU GOLIKE(R) Product Line with More Convenient, Chewable Tablet Option GENEVA, SWITZERLAND / ACCESSWIRE / September 9, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
GENEVA, SWITZERLAND / ACCESSWIRE / September 8, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics Comments on Certain Statements Made by NRx Pharmaceuticals in its Registration Statement on Form S-1 Filed on September 3, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / September 7, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), commented today on statements made by NRx Pharmaceuticals, Inc.... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Reports Regulatory Clearance in Germany to Commence a Multicenter, Double-blind, Randomized Phase 2 Clinical Trial to Evaluate Inhaled Aviptadil for the Treatment of Sarcoidosis
GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports that U.S. Collaboration Partner has Announced a New Finding from Aviptadil Phase 2b/3 Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
GENEVA, SWITZERLAND / ACCESSWIRE / August 31, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19
GENEVA, SWITZERLAND / ACCESSWIRE / August 19, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics' Lead Candidate Gets US Orphan Drug Tag In Sarcoidosis
The FDA has granted Orphan Drug Designation to Relief Therapeutics Holding AG's (OTC: RLFTF) for RLF-100 (aviptadil), an inhaled formulation, for... 
Via Benzinga
Exposures Product Safety
Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis
From RELIEF THERAPEUTICS Holding AG
Via Business Wire
Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia
GENEVA, SWITZERLAND / ACCESSWIRE / July 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita
Acquisition Expands Scope of Development of Inhaled Formulation of Aviptadil GENEVA, SWITZERLAND / ACCESSWIRE / July 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief "), a... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Relief Therapeutics Announces CHF 15 Million Private Placement
GENEVA, SWITZERLAND / ACCESSWIRE / July 26, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company seeking to provide patients... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?
Extending yesterday's gain, NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock is up more than 26% during the premarket trading on Friday. NRx's stock opened Thursday... 
Via Benzinga
Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil
GENEVA, SWITZERLAND / ACCESSWIRE / July 23, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting
Shares being used in part for payments related to AdVita and APR acquisitions Acquisitions are part of Relief's transformation into a fully integrated diversified commercial-stage pharmaceutical... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19
GENEVA, SWITZERLAND / ACCESSWIRE / July 20, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial
GENEVA, SWITZERLAND / ACCESSWIRE / July 13, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR
Transforms Relief into a fully integrated commercial-stage biopharmaceutical company Acquisition further diversifies Relief's pipeline with both commercial products and clinical-stage programs and... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority
GENEVA, SWITZERLAND / June 21, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil)... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
GENEVA, SWITZERLAND / ACCESSWIRE / June 16, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
GENEVA, SWITZERLAND / ACCESSWIRE / June 2, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure
NRx Pharmaceuticals (NASDAQ: NRXP) has applied with FDA requesting Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for critically ill COVID-19... 
Via Benzinga
Exposures COVID-19 Product Safety
Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer
GENEVA, SWITZERLAND / ACCESSWIRE / May 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG
GENEVA, SWITZERLAND / ACCESSWIRE / May 27, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders
GENEVA, SWITZERLAND / ACCESSWIRE / May 18, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
GENEVA, SWITZERLAND / ACCESSWIRE / May 17, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.